Corticosteroid-induced hyperglycemia is increased 10-fold in patients with pemphigus

International Journal of Dermatology

Volumn 51, Issue 10, 2012, Pages 1248-1252

  Alavi, Afsaneh ^a   Lowe, Julia ^a,b   Walsh, Scott ^a   Juurlink, David ^a,b   Mortaz Hedjri, Soroush ^b   Shear, Neil H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PREVALENCE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; CROSS-SECTIONAL STUDIES; DERMATOLOGIC AGENTS; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERGLYCEMIA; INCIDENCE; MALE; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; PEMPHIGUS; PREVALENCE; TREATMENT OUTCOME;

EID: 84866538181     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05470.x     Document Type: Article

References (25)

1. Kenneth D, Kochanek MA, Sherry L, et al. National Vital Statistics Report 53. 2004. http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_05acc.pdf. (Accessed October 25th, 2010).
2. Wu S, Armstrong DG. Risk assessment of the diabetic foot and wound. Int Wound J 2005; 2: 17-24.
3. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycemia. Lancet 2009; 373: 1798-1807.
4. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycemia on infectious disease hospitalization and outcome. Diabetologia 2007; 50: 549-554.
5. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol 1996; 132: 203-212.
6. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end-points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
7. Mittmann N, Chan B, Knowles S, et al. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg 2006; 10: 222-227.
8. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-111.
9. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
10. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25: 489-505.
11. Burén J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin signaling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol 2002; 146: 419-429.
12. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007; 11: 462-481.
13. Australian Longitudinal Study of Women's Health. Women, health and ageing. http://www.alswh.org.au/surveys.html. (Accessed October 25th, 2010).
14. Bhattacharyya OK, Estey EA, Cheng AY. Canadian Diabetes Association 2008. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009; 55: 39-43.
15. Borch-Johnsen K, Colagiuri S. Diagnosing diabetes - time for a change? Diabetologia 2009; 52: 2247-2250.
16. Manson SC, Brown RE, Cerulli A. The cumulative burden of oral corticosteroid side-effects and the economic implications of steroid use. Respir Med 2009; 103: 975-994.
17. Korman N. Pemphigus. J Am Acad Dermatol 1988; 6: 1219-1238.
18. Compston J, Reid DM, Boisdron J, et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 2008; 19: 1247-1250.
19. Wolverton SE. Comprehensive Dermatologic Drug Therapies. Saunders: Elsevier, 2007; 127-157.
20. Ljubojević S, Lipozencić J, Brenner S, Budimcić D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol 2002; 16: 599-603.
21. Alexander TH, Weisman MH, Derebery JM, et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol Neurotol 2009; 30: 443-448.
22. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
23. Iwamoto T, Kagawa Y, Naito Y, et al. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004; 24: 508-514.
24. Chuang T, Korkii W, Soltani K, et al. Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case-control study. J Am Acad Dermatol 1984; 11: 1099-1102.
25. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 469-474.